A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 3 to 4
  2. Recruitment opened Show 4 more changesShow less
    • Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC
    • Trial sites expanded: 0 → 3 locations
    • Start date changed from estimate of Sep 15, 2026 to Sep 10, 2026
    • Eligibility criteria expanded, about 4 words
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
410 trials monitored
See 27 trials at risk
The purpose of this trial is to compare what happens to MK-1406 in the body of healthy participants when it is given as 2-injections and 3-injections. Researchers also want to learn about the safety of MK-1406 and if people tolerate it.
Trial Details
NCT Number NCT07743151
Lead Sponsor Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Healthy
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov